Business Wire

Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations ...
BioWorld

Vertex feels no pain in new, head-to-head CF data

BioWorld - Saturday, June 29, 2024 See today's BioWorld Home » Vertex feels no pain in new, head-to-head CF data ...
Forbes

Vertex Is Writing A New Playbook For Pharma R&D. And It’s Working.

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...
Seeking Alpha

Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership

Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...
FiercePharma

Vertex jumps to TreeFrog to enhance production of Type 1 diabetes cell therapy candidates

Following success in cystic fibrosis and sickle cell disease, Vertex’s next big leap is Type 1 diabetes (T1D). Helping the Boston company develop three pipeline candidates in the indication will be ...
Seeking Alpha

Vertex Pharmaceuticals: A Long-Term Growth Monster

Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown ...